MGC Pharmaceuticals “totally understands” CimetrA after MoA study

–News Direct–

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief medical officer Nadya Lisovoder speaks to Proactive's Thomas Warner after announcing the completion of an in-vitro pre-clinical mechanism of action (MoA) study for the European based bio-pharma company's CimetrA platform.

Lisovoder says that the fact MGC “totally understands” CimetrA represents a “very important step” in the development process.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/mgc-pharmaceuticals-totally-understands-cimetra-after-moa-study-226216324